Elanco Animal Health Inc
ELANAPI behind this page
ELAN Q1 2026 request
Playground key active
/api/financials?ticker=ELAN&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 1,371 | 1,193 | +14.9% |
Show Product Lines breakouts |
|||
| Cattle | 316 | 272 | +16.2% |
| Contract Manufacturing [Member] | 19 | 12 | +58.3% |
| Farm Animal: | 642 | 546 | +17.6% |
| Pet Health | 710 | 635 | +11.8% |
| Poultry | 230 | 189 | +21.7% |
| Swine | 96 | 85 | +12.9% |
Show Business Segments breakouts |
|||
| Reportable Segment | 1,371 | 1,193 | +14.9% |
Show Geography breakouts |
|||
| Non Us | 766 | 639 | +19.9% |
| US | 605 | 554 | +9.2% |
| Cost of Revenue | 586 | 509 | +15.1% |
Show Business Segments breakouts |
|||
| Reportable Segment | 586 | 509 | +15.1% |
| Gross Profit | 785 | 684 | +14.8% |
Show Business Segments breakouts |
|||
| Reportable Segment | 785 | 684 | +14.8% |
| Research & Development | 97 | 94 | +3.2% |
Show Business Segments breakouts |
|||
| Reportable Segment | 97 | 94 | +3.2% |
| Selling, General & Administrative | 381 | 341 | +11.7% |
| Amortization Of Intangible Assets | 138 | 128 | +7.8% |
| Restructuring Costs And Asset Impairment Charges | 16 | 9 | +77.8% |
| Interest Expense Operating | 57 | 40 | +42.5% |
Show Business Segments breakouts |
|||
| Reportable Segment | 57 | 40 | +42.5% |
| Other Operating Income Expense Net | 9 | 12 | -25.0% |
Show Business Segments breakouts |
|||
| Reportable Segment | 9 | 12 | -25.0% |
| Income Before Taxes | 87 | 60 | +45.0% |
| Income Tax Expense (Benefit) | 30 | -7 | +528.6% |
Show Business Segments breakouts |
|||
| Reportable Segment | 30 | -7 | +528.6% |
| Net Income | 57 | 67 | -14.9% |
Show Business Segments breakouts |
|||
| Reportable Segment | 57 | 67 | -14.9% |
Show Equity Components breakouts |
|||
| Retained Earnings | 57 | 67 | -14.9% |
| EPS (Basic) | 0.11 | 0.14 | -21.4% |
| EPS (Diluted) | 0.11 | 0.13 | -15.4% |
| Wtd Avg Shares (Basic) | 497.7 | 495.1 | +0.5% |
| Wtd Avg Shares (Diluted) | 506 | 499.1 | +1.4% |
| Total Costs & Expenses (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | 574 | 480 | +19.6% |
| Sales & Marketing (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | 256 | 225 | +13.8% |
| General & Administrative (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | 125 | 116 | +7.8% |
| Interest Income (Q) | — | — | — |
Show Derivative Risk breakouts |
|||
| Foreign Exchange Contract · Designated As Hedging Instrument | 11 | 11 | 0.0% |
| Comprehensive Income | -35 | 255 | -113.7% |
| Other Comprehensive Income | -92 | 188 | -148.9% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -5 | -1 | -400.0% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | 12 | -29 | +141.4% |
| Accumulated Other Comprehensive Income | -92 | 188 | -148.9% |
| Accumulated Translation Adjustment | -99 | 218 | -145.4% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 428 | 487 | -12.1% |
| Accounts Receivable | 1,084 | 970 | +11.8% |
Show Product Lines breakouts |
|||
| Product | 117 | 118 | -0.8% |
| Other Receivables Net Current | 70 | 90 | -22.2% |
| Inventory | 1,717 | 1,592 | +7.9% |
| Prepaid Expenses & Other Current Assets | 285 | 301 | -5.3% |
| Total Current Assets | 3,584 | 3,440 | +4.2% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 1,395 | 1,047 | +33.2% |
| Goodwill | 4,723 | 4,508 | +4.8% |
| Intangible Assets Net Excluding Goodwill | 3,225 | 3,634 | -11.3% |
| Other Non-Current Assets | 295 | 312 | -5.4% |
| Total Assets | 13,222 | 12,941 | +2.2% |
| Current Liabilities | |||
| Accounts Payable | 372 | 330 | +12.7% |
| Deferred Revenue (Current) | 400 | 319 | +25.4% |
| Long Term Debt And Capital Lease Obligations Current | 73 | — | — |
| Other Liabilities Current | 817 | 576 | +41.8% |
| Total Current Liabilities | 1,662 | 1,269 | +31.0% |
| Non-Current Liabilities | |||
| Long Term Debt And Capital Lease Obligations | 3,918 | — | — |
| Sale Of Future Revenue Liability Noncurrent | 309 | — | — |
| Deferred Tax Liabilities | 366 | 481 | -23.9% |
| Other Non-Current Liabilities | 467 | 487 | -4.1% |
| Total Liabilities | 6,722 | 6,588 | +2.0% |
| Long-Term Debt | 3,736 | — | — |
| Stockholders' Equity | |||
| Additional Paid-In Capital | 8,858 | 8,819 | +0.4% |
| Retained Earnings | -2,125 | -1,883 | -12.9% |
| Accumulated Other Comprehensive Income | -233 | -583 | +60.0% |
| Total Stockholders' Equity | 6,500 | 6,353 | +2.3% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | 85 | 57 | +49.1% |
| Accumulated Other Comprehensive Income | -233 | -583 | +60.0% |
| Accumulated Translation Adjustment | -318 | -648 | +50.9% |
| Additional Paid In Capital | 8,858 | 8,819 | +0.4% |
| Retained Earnings | -2,125 | -1,883 | -12.9% |
| Total Liabilities & Equity | 13,222 | 12,941 | +2.2% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 172 | 161 | +6.8% |
| Stock-Based Compensation | 21 | 15 | +40.0% |
| Purchase And Sale Agreement Sold Portion Of Royalty Revenue | -9 | — | — |
Show Counterparty Name breakouts |
|||
| Blackstone Life Sciences and Blackstone Credit & Insurance | -9 | — | — |
| Purchase And Sale Agreement Interest On Liability For Sale Of Future Revenue | 14 | — | — |
Show Counterparty Name breakouts |
|||
| Blackstone Life Sciences and Blackstone Credit & Insurance | 14 | — | — |
| Increase Decrease In Operating Capital | -263 | -237 | -11.0% |
| Other Operating Activities Cash Flow Statement | 21 | -10 | +310.0% |
| Net Cash from Operations | 13 | -4 | +425.0% |
| Investing Activities | |||
| Capital Expenditures | -51 | -65 | +21.5% |
| Other Investing Activities | -9 | -2 | -350.0% |
| Net Cash from Investing | -60 | -58 | -3.4% |
| Financing Activities | |||
| Repayments Of Senior Debt | -16 | -13 | -23.1% |
| Tax Withholding for Share Compensation | -34 | -13 | -161.5% |
| Proceeds From Payments For Other Financing Activities | -15 | -7 | -114.3% |
| Net Cash from Financing | -65 | 52 | -225.0% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -5 | 29 | -117.2% |
| Net Change in Cash | -117 | 19 | -715.8% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 428 | 487 | -12.1% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.